Today on DrugResearcher.com   Eisai continues biologics push with $3.9bn MGI Pharma buy Galapagos branches out with new GSK deal ACD/Labs takes the stress out of NMR spectral analysis BMS reveals plans to trim the fat Morphosys to exit fee-for-service upon Novartis deal

Related Industry News   William Ransom & Son recall false contaminated products Millipore partners Rohm and Haas to develop new chromatography media Abbott cuts jobs, closes plant in Ireland Eisai selects Singapore as Asia trials hub

Breaking News on Drug Discovery
Daily  Monday 10 December 2007		Forward to a colleague

	Sponsored Link Excellent value for money for routine moisture determination The TitraLab 580 and 585 Volumetric Karl Fischer Workstations are ideal for fast and accurate moisture determination whether you are working with solids or liquids. Operation is simple thanks to pre-programmed functions and dedicated buttons for solvent addition and cell... Click Here Access Full Stories Eisai continues biologics push with $3.9bn MGI Pharma buy Japanese drugmaker Eisai has agreed to buy US biopharma firm MGI Pharma for $3.9bn (€2.7bn) in a bid to expand its US presence and strengthen its oncology pipeline... Read Galapagos branches out with new GSK deal GlaxoSmithKline (GSK) is the latest drug firm to involve Galapagos in a new development partnership, in a deal worth up to €218m for the Belgian biotech... Read ACD/Labs takes the stress out of NMR spectral analysis ACD/Labs has unveiled a new programme designed to help synthetic chemists reduce the amount of time required to spend on NMR (nuclear magnetic resonance) data analysis... Read BMS reveals plans to trim the fat Bristol-Myers Squibb (BMS) has finally detailed its plans to trim the fat and save cash, months after first revealing that big changes would be on the cards... Read Morphosys to exit fee-for-service upon Novartis deal Morphosys has landed in the money after scoring a lucrative 10 year antibody development deal with Novartis and as a result, will now place all its eggs in one basket and cut ties with its fee-for-service customers... Read
	All News Headlines for: December | November | October
	Product Presentation ZIC®-HILIC Separation of Polar and Hydrophilic Compounds The technology leading ZIC®HILIC and ZIC®-pHILIC separation media, designed for polar and hydrophilic compounds, are tools for clinical analysis and to solve separation and purification problems in research, development and production of pharmaceuticals. ZIC®-HILIC... Click Here
	Related Industry News William Ransom & Son recall false contaminated products UK-based William Ransom & Son has been advised to voluntarily recall certain products following a false contamination scare at its Witham, Essex, facility... Read Millipore partners Rohm and Haas to develop new chromatography media Separations expert Millipore is collaborating with Rohm and Haas Company to develop new high-performance chromatography products for use in biopharmaceutical manufacturing... Read Abbott cuts jobs, closes plant in Ireland Abbott is to shut its doors on its Galway, Ireland, facility - taking 500 jobs with it - as the market moves into murky waters over the future of vascular stents... Read Eisai selects Singapore as Asia trials hub Eisai is planning to step up its clinical research presence in Asia and has chosen Singapore as a hub from which to coordinate its research activities... Read Weekly Comment Paediatric drugs and testing highlighted The importance of paediatric drug formulations and clinical trials in children was highlighted at this month's American Association of Pharmaceutical Scientists (AAPS) conference in San Diego. Read Previous Headlines Microfluidics promises a bright future for cell-based assays UK researchers have published results that show that microfluidic devices can provide robust quantitative pharmacological information from low numbers of single cells... Read Drugs moving into the clinic: 38 The latest in a series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators... Read Separating mixtures in an NMR machine Canadian researchers have devised a method of extracting the complete proton NMR (nuclear magnetic resonance) spectra for a component of a mixture without the need for physical separation... Read Addex and Merck target new cure for Parkinson's Merck & Co. has entered into an exclusive collaboration and licensing deal with Addex Pharma to develop a new class of orally available Parkinson's therapies... Read Drugs moving into the clinic: 37 The latest in a series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators... Read Technical / White Papers, Case studies, Web casts Benefits of integrating human tissue research in drug discovery - Technical / White Paper Manufacturing Variations in Polysorbate Batches - Technical / White Paper Product Information - brochures, Web centers ZIC®-HILIC Separation of Polar and Hydrophilic Compounds - Product Presentation DAICEL chiral chromatography products - Company Profile Rapid HPLC method development with ChromSword®Auto software - Product Presentation Separation of polar compounds - Application Notes Product Innovation Alerts - Free of Charge Indicate your research interests and receive alerts on relevant products and market innovations Analysis and instrumentation Assays and screening Cell culture & Equipment Chromatography Compounds and consumables Contract services (outsourcing) Drug discovery Genomics / Proteomics Informatics & IT Lab equipment & consumables Liquid handling and automation Liquid handling and sample preparation Production technologies Separation and purification

	Free Newsletters for Pharmaceuticals Access now !Choose from over 20 industry e-newsletters Access Decision News Media e-newsletters for the food, beverage & nutrition industries, click here
	Forward to a colleague

	To continue to receive this newsletter in your inbox, please add newsletter@DrugResearcher.com to your address book
	Update preferences | Change your email address | Unsubscribe
	Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback
	© 2007 - Decision News Media S.A.S - All Rights Reserved Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France http://www.decisionnewsmedia.com